Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valacyclovir

E P Acosta1, C V Fletcher

  • 1Department of Pharmacy Practice, College of Pharmacy, University of Minnesota 55455, USA.

The Annals of Pharmacotherapy
|February 1, 1997
PubMed
Summary
This summary is machine-generated.

Valacyclovir, a prodrug of acyclovir, offers improved bioavailability and is effective for treating herpesvirus infections. Its enhanced systemic exposure makes it promising for immunocompromised patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2025
Same author

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

The Journal of antimicrobial chemotherapy·2020
Same author

Pharmacokinetics of tenofovir during pregnancy and postpartum.

HIV medicine·2015
Same author

Helicase-primase as a target of new therapies for herpes simplex virus infections.

Clinical pharmacology and therapeutics·2015
Same author

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.

Clinical pharmacology and therapeutics·2014
Same author

Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo.

Clinical pharmacology and therapeutics·2010
Same journal

Association Between Prior PARP Inhibitor Maintenance Therapy and Myelosuppression During Subsequent Chemotherapy in Ovarian Cancer.

The Annals of pharmacotherapy·2026
Same journal

Prolonged Response to Nivolumab in Metastatic Vulvar Carcinoma: Should Immunotherapy be Continued and for How Long? A Debatable Issue!

The Annals of pharmacotherapy·2026
Same journal

Stability of Ceftazidime-Avibactam: Changes in Regulatory Information and Implications for Preparation.

The Annals of pharmacotherapy·2026
Same journal

Impact of Early Dose Adjustment of Piperacillin/Tazobactam on Mortality in Critically Ill Patients With Acute Kidney Injury: A Retrospective Multicenter Cohort Study.

The Annals of pharmacotherapy·2026
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology and Virology
  • Clinical Therapeutics

Background:

  • Herpesvirus infections pose significant health challenges.
  • Valacyclovir is an antiviral medication used for herpesvirus treatment.

Purpose of the Study:

  • To review the clinical pharmacology, antiviral activity, and efficacy of valacyclovir.
  • To discuss therapeutic considerations for valacyclovir in herpesvirus infections.

Main Methods:

  • Literature searches of MEDLINE (1982-1996) focused on valacyclovir.
  • Inclusion of clinical and basic science studies specifically on valacyclovir.

Main Results:

  • Valacyclovir, a prodrug of acyclovir, exhibits 54% bioavailability versus 20% for oral acyclovir.
  • Achieves higher systemic acyclovir exposure, comparable to intravenous administration at higher doses.

Related Experiment Videos

  • Demonstrates at least equivalent efficacy to acyclovir in managing pain and healing genital herpes lesions.

    • Conclusions:

    • Valacyclovir offers superior bioavailability and efficacy compared to acyclovir.
    • Its safety profile and increased systemic exposure support further investigation in immunocompromised individuals with herpes group viral infections.